ASAP announces new teams joining the Collaborative Research Network! Learn More
Aligning Science Across Parkinson's Logo Text
Submit site search
  • In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts

    By on

    Loss-of-function mutations in VPS13C are responsible for rare cases of familial early onset Parkinson’s disease. Using cryo-ET, the authors provide in-situ evidence for a bridge-model of VPS13 in lipid transport.

  • His-ATG3-T244A

    By on

    Plasmid for ATG3 T244A mutant overexpression in E.Coli.

  • In Silico analysis links the NSL complex to Parkinson’s disease and the mitochondria – Protein-protein interaction data to functional enrichment analysis

    By on

    A bioinformatics approach taken to investigate the interactome of the NSL complex, to unpick its relevance to Parkinson’s disease progression.

  • pCAG-GST-ATG13 (363-392)

    By on

    Plasmid for mammalian expression of GST tagged ATG13 (363-392).

  • Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9

    By on

    Autophagy is a cellular degradation pathway essential for neuronal health and function. Autophagosome biogenesis occurs at synapses, is locally regulated, and increases in response to neuronal activity. The mechanisms that couple autophagosome biogenesis to synaptic activity remain unknown. In this study, we determine that trafficking of ATG-9, the only transmembrane protein in the core autophagy pathway, links the synaptic vesicle cycle with autophagy. ATG-9-positive vesicles in C. elegans are generated from the trans-Golgi network via AP-3-dependent budding and delivered to presynaptic sites. At presynaptic sites, ATG-9 undergoes exo-endocytosis in an activity-dependent manner. Mutations that disrupt endocytosis, including a lesion in synaptojanin 1 associated with Parkinson’s disease, result in abnormal ATG-9 accumulation at clathrin-rich synaptic foci and defects in activity-induced presynaptic autophagy. Our findings uncover regulated key steps of ATG-9 trafficking at presynaptic sites and provide evidence that ATG-9 exo-endocytosis couples autophagosome biogenesis at presynaptic sites with the activity-dependent synaptic vesicle cycle.

  • Open science takes on Parkinson’s disease

    By on

    This article explains the Aligning Science Across Parkinson's (ASAP) initiative's commitment to open science by taking a deep look into how the initiative contributes to the open science movement.

  • pBMN HA-NDP52

    By on

    Plasmid: For expression of the mammalian NDP52 tagged with HA.

  • Hippocampal Neuronal Culture

    By on

    This protocol describes the procedure for hippocampal neuronal cultures from new - born mouse pups.

  • 2BT-His-TEV-cs-ATG3_R265A

    By on

    DISCONTINUED - Plasmid for bacterial Expression of human ATG3 R265A.

  • pAC150 GFP-RFP-LGALS3 R186S

    By on

    Plasmid

  • Bile acids and neurological disease

    By on

    This review will focus on how bile acids are being used in clinical trials to treat neurological diseases due to their central involvement with the gut-liver-brain axis and their physiological and pathophysiological roles in both normal brain function and multiple neurological diseases. The synthesis of primary and secondary bile acids species and how the regulation of the bile acid pool may differ between the gut and brain is discussed. The expression of several bile acid receptors in brain and their currently known functions along with the tools available to manipulate them pharmacologically are examined, together with discussion of the interaction of bile acids with the gut microbiome and their lesser-known effects upon brain glucose and lipid metabolism. How dysregulation of the gut microbiome, aging and sex differences may lead to disruption of bile acid signalling and possible causal roles in a number of neurological disorders are also considered. Finally, we discuss how pharmacological treatments targeting bile acid receptors are currently being tested in an array of clinical trials for several different neurodegenerative diseases

  • LC3-lipidation-assay

    By on

    Protocol for an in vitro LC3 lipidation assay using purified proteins and synthetic liposomes.

  • Membrane Tube Image Analysis

    By on

    This protocol details Membrane Tube Image Analysis.

  • pCAG-OSF-ATG13 (2-197)-L151D

    By on

    Plasmid for expression of human ATG13 HORMA L151D mutant in mammalian cells.

  • Measurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA

    By on

    Measurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA

  • Structural basis for the specificity of PPM1H phosphatase for Rab GTPases

    By on

    Raw data associated with DOI: 10.15252/embr.202152675

  • pU6-pegRNA-LRRK2-G2019S-3a

    By on

    It can be used to introduce LRRK2-G2019S mutation using prime editing.

  • Immunochemistry on paraffin sections

    By on

    Protocol for immunochemistry on paraffin sections.

  • Sample Collection and Processing for RNA Analysis

    By on

    This protocol delineates the steps taken to collect frozen postmortem human brain samples and process them for RNA extraction and analysis.

Load More
Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.